Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $695,070.09 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Francis Lo sold 39,741 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $17.49, for a total value of $695,070.09. Following the transaction, the insider owned 250,934 shares in the company, valued at approximately $4,388,835.66. The trade was a 13.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Francis Lo also recently made the following trade(s):

• On Wednesday, April 8th, Francis Lo sold 22,564 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $15.07, for a total value of $340,039.48.
• On Wednesday, March 11th, Francis Lo sold 30,593 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.08, for a total value of $430,749.44.

Adaptive Biotechnologies Price Performance

ADPT opened at $17.07 on Thursday. The stock’s 50 day simple moving average is $14.41 and its 200 day simple moving average is $15.67. Adaptive Biotechnologies Corporation has a 1 year low of $9.90 and a 1 year high of $20.76. The firm has a market cap of $2.73 billion, a price-to-earnings ratio of -51.73 and a beta of 2.15.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The business had revenue of $70.87 million for the quarter, compared to analyst estimates of $61.03 million. During the same period last year, the company earned ($0.20) EPS. Adaptive Biotechnologies’s revenue for the quarter was up 35.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.

Wall Street Analyst Weigh In

ADPT has been the subject of several research analyst reports. BTIG Research reiterated a “buy” rating and issued a $22.00 price objective on shares of Adaptive Biotechnologies in a report on Wednesday, May 6th. Morgan Stanley dropped their price objective on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Wall Street Zen cut Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. TD Cowen increased their price objective on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Monday, April 20th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $19.57.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ADPT. AQR Capital Management LLC lifted its stake in shares of Adaptive Biotechnologies by 45.8% in the 1st quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock valued at $2,265,000 after purchasing an additional 97,444 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Adaptive Biotechnologies by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock valued at $511,000 after purchasing an additional 2,914 shares during the period. Caxton Associates LLP purchased a new position in shares of Adaptive Biotechnologies in the 1st quarter valued at approximately $93,000. New York State Common Retirement Fund lifted its stake in shares of Adaptive Biotechnologies by 39.2% in the 2nd quarter. New York State Common Retirement Fund now owns 47,258 shares of the company’s stock valued at $551,000 after purchasing an additional 13,300 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its stake in shares of Adaptive Biotechnologies by 728.8% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 379,120 shares of the company’s stock valued at $4,417,000 after purchasing an additional 333,379 shares during the period. Hedge funds and other institutional investors own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.